Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted two recently-published scientific articles on the potential benefits of its lead candidate, levosimendan, in
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that John Kelley, Chief Executive Officer, will present a company overview at the Cowen & Company 35th Annual
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today confirmed Paula Bokesch, M.D. assumed her role as the Company’s Chief Medical Officer on February 14, 2015.
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced the appointment of Paula Bokesch, M.D. as Chief Medical Officer, effective February 14, 2015.
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced financial results for the second quarter fiscal year 2015 ended October 31, 2014.
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company will host a conference call and live audio webcast on Wednesday, December 17, 2014, at 8:30
Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced financial results for the first quarter fiscal year 2015 ended July 31,
Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the first patients have been enrolled in the LEVO-CTS Phase 3 trial
